Lumexa Imaging Holdings, Inc. $LMRI Shares Newly Bought by Brooklands Fund Management Ltd

Key Points

• Brooklands Fund Management initiated a position of 2.1 million Lumexa Imaging shares worth approximately $21.6 million, representing about 2.19% of the company and 3.2% of Brooklands’ portfolio.
• Analysts are broadly positive, with a consensus “Buy” rating and an average price target of $16.40, compared with the stock’s recent opening price of $11.73.
• Lumexa reported quarterly EPS of $0.20, beating the $0.03 consensus estimate, on revenue of $264.16 million; the company issued fiscal 2026 EPS guidance of $0.71 to $0.77.

Brooklands Fund Management Ltd purchased a new position in shares of Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,105,059 shares of the company's stock, valued at approximately $21,577,000. Lumexa Imaging accounts for approximately 3.2% of Brooklands Fund Management Ltd's investment portfolio, making the stock its 15th largest holding. Brooklands Fund Management Ltd owned about 2.19% of Lumexa Imaging as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Strs Ohio acquired a new position in shares of Lumexa Imaging in the 1st quarter worth approximately $38,000. State of Alaska Department of Revenue bought a new stake in shares of Lumexa Imaging in the 3rd quarter worth about $46,000. PNC Financial Services Group Inc. bought a new stake in shares of Lumexa Imaging in the 1st quarter worth about $63,000. Principal Financial Group Inc. increased its position in shares of Lumexa Imaging by 1.2% during the 1st quarter. Principal Financial Group Inc. now owns 664,136 shares of the company's stock worth $5,712,000 after purchasing an additional 7,875 shares in the last quarter. Finally, State of Wyoming acquired a new stake in shares of Lumexa Imaging during the 1st quarter worth about $91,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Deutsche Bank Aktiengesellschaft set a $16.00 price target on shares of Lumexa Imaging in a research report on Thursday, August 13th. Barclays lifted their target price on shares of Lumexa Imaging from $9.00 to $13.00 and gave the company an "overweight" rating in a research note on Friday, August 28th. Truist Financial started coverage on Lumexa Imaging in a report on Monday, October 5th. They issued a "buy" rating and a $18.00 target price on the stock. UBS Group restated a "strong-buy" rating on shares of Lumexa Imaging in a research report on Monday, September 28th. Finally, KeyCorp started coverage on Lumexa Imaging in a research note on Thursday, September 24th. They issued an "overweight" rating and a $18.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $16.40.

Lumexa Imaging Stock Up 0.9%

Shares of LMRI opened at $11.73 on Friday. The business's fifty day moving average price is $11.11 and its two-hundred day moving average price is $11.11. Lumexa Imaging Holdings, Inc. has a 52 week low of $6.45 and a 52 week high of $19.45. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 1.40.

Lumexa Imaging (NASDAQ:LMRI - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.17. The firm had revenue of $264.16 million for the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. As a group, equities analysts forecast that Lumexa Imaging Holdings, Inc. will post 0.25 EPS for the current year.

Lumexa Imaging Company Profile

Lumexa Imaging is a U.S.-based provider of outpatient diagnostic imaging and radiology services. The company operates imaging centers and offers services designed to support physicians, hospitals, health systems and patients in the diagnosis and monitoring of medical conditions.

Its service portfolio includes advanced imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound and X-ray. Lumexa also provides radiology-related services, including image interpretation and support for referring healthcare providers, through fixed-site and mobile imaging operations.

The company serves communities across the United States through its network of outpatient facilities and healthcare partnerships.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.